NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on handTradingView·Aug 17 at 07:03 AMNRXP+5.41%
NRx Pharmaceuticals schedules conference call on quarterly results and corporate updatePUBT·Aug 17 at 06:03 AMNRXP+5.41%
NRXP: FDA review nearly complete; manufacturing scaled for launch to address U.S. ketamine shortageQuartr·Aug 10 at 09:52 AMNRXP+5.41%
BTIG Research Cuts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $10.00Market Beat·Aug 7 at 01:24 PMNRXP+5.41%
FDA flags packaging certification as sole major deficiency for NRx preservative-free ketamine ANDA approvalPUBT·Aug 7 at 06:01 AMNRXP+5.41%
The Market's Island of Misfit Toys: AI Posers, Meme Stocks, and One Real WinnerGlobal Report·Aug 4 at 04:17 AMPOAS-2.14%FBGL+2.69%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Jul 31 at 04:06 PMAMIX-10.83%PFSA-44.22%
NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuitPUBT·Jun 25 at 03:01 PMNRXP+5.41%
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)Tip Ranks·Jun 25 at 07:36 AMNRXP+5.41%
NRx subsidiary HOPE Therapeutics begins patient treatments using Zeta Surgical TMS navigation systemPUBT·Jun 25 at 06:02 AMNRXP+5.41%
